Multiple Myeloma Coverage from Every Angle

Rare Case of Refractory Multiple Myeloma With Dura Mater Involvement

By: Kayci Reyer
Posted: Monday, July 1, 2019

A case study published in OncoTargets and Therapy featured a patient with refractory multiple myeloma who experienced dura mater involvement. Disease progression to this part of the brain and spinal cord is rare in multiple myeloma, occurring in up to 1% of cases. And in this case, the 49-year-old woman responded to lenalidomide treatment, according to Yafei Wang, MD, of the Tianjin Medical University Hospital in China, and colleagues.

The patient initially presented with right rib pain lasting 4 months. A positron-emission tomography–computed tomography scan revealed a soft-tissue mass on the right fifth rib. The laboratory findings revealed an immunoglobulin D (IgD)-lambda type of monoclonal immunoglobulin, and bone marrow biopsy showed 80% lambda-restricted, CD138 and CD38 double-positive plasma cells. The patient was then diagnosed with IgD-lambda multiple myeloma. She underwent two cycles of bortezomib/doxorubicin/dexamethasone (PAD), after which she achieved a partial response and continued PAD treatment for two additional cycles.

After treatment, she reported escalating jaw numbness and mild dysphagia. Magnetic resonance imaging (MRI) showed a thickening of dura mater and an increased strength of signal. The researchers noted, “Flow cytometry of the bone marrow showed 2.22% lambda-restricted, CD138- and CD38-positive plasma cells.”

The patient began an aggressive treatment regimen intended to cross the blood-brain barrier, receiving 25 mg of lenalidomide on days 1 to 21; 500 mg of cyclophosphamide on days 1, 8, 15, and 21; and 30 mg of dexamethasone on days 1 to 4 and 12 to 15. After a single cycle of this treatment, all symptoms were eradicated, the patient’s platelet count returned to normal, and the serum-free lambda light chain value decreased to 51.6 mg/L (from 267.5 mg/L after induction treatment). A follow-up MRI showed a significant decrease in both dura mater masses and signal strength.

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.